{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"9.3","upperLimit":"22.4","value":"13.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"title":"Core n=36"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.1","upperLimit":"70.1","value":"22.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"}],"units":"Participants"}],"title":"Extension n=20"}],"denoms":[{"counts":[{"groupId":"OG000","value":"68"}],"units":"Participants"}],"description":"Duration of controlled or partially controlled response is defined as the period starting from the date of patient's first normalization (mUFC ≤ 1.0 x ULN) or at least 50% reduction from baseline up to the date when the patient's mUFC \\> 1.0 x ULN and the reduction from baseline falls to less than 50% from the first time","dispersionType":"95% Confidence Interval","groups":[{"description":"Pasireotide montherapy (0.6 mg bid to 0.9 mg bid) was administered until the biochemical control was achieved and if not achieved, a combination was administered: pasireotide (0.9 mg bid) + cabergoline (0.5 QD to 1 mg QD). Patients were able to add cabergoline at anytime during core and extension","id":"OG000","title":"All Patients"}],"paramType":"MEDIAN","populationDescription":"Core and extension full analysis set","reportingStatus":"POSTED","timeFrame":"from the date patient's first normalization (mUFC ≤ 1.0xULN) or at least 50% reduction from baseline up to the date when the patient's mUFC > 1.0 x ULN","title":"Duration (Weeks) of Controlled or Partially Controlled Response","type":"SECONDARY","unitOfMeasure":"weeks"}